Success Metrics

Clinical Success Rate
90.0%

Based on 18 completed trials

Completion Rate
90%(18/20)
Active Trials
12(18%)
Results Posted
22%(4 trials)
Terminated
2(3%)

Phase Distribution

Ph not_applicable
52
76%
Ph early_phase_1
2
3%
Ph phase_1
4
6%
Ph phase_2
5
7%
Ph phase_4
2
3%
Ph phase_3
1
1%

Phase Distribution

6

Early Stage

5

Mid Stage

3

Late Stage

Phase Distribution66 total trials
Early Phase 1First-in-human
2(3.0%)
Phase 1Safety & dosage
4(6.1%)
Phase 2Efficacy & side effects
5(7.6%)
Phase 3Large-scale testing
1(1.5%)
Phase 4Post-market surveillance
2(3.0%)
N/ANon-phased studies
52(78.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

62.1%

18 of 29 finished

Non-Completion Rate

37.9%

11 ended early

Currently Active

12

trials recruiting

Total Trials

68

all time

Status Distribution
Active(29)
Completed(18)
Terminated(11)
Other(10)

Detailed Status

Completed18
Not yet recruiting17
Recruiting11
unknown10
Withdrawn9
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
68
Active
12
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.0%)
Phase 14 (6.1%)
Phase 25 (7.6%)
Phase 31 (1.5%)
Phase 42 (3.0%)
N/A52 (78.8%)

Trials by Status

active_not_recruiting11%
completed1826%
terminated23%
withdrawn913%
not_yet_recruiting1725%
recruiting1116%
unknown1015%

Recent Activity

Clinical Trials (68)

Showing 20 of 68 trialsScroll for more
NCT05357690Phase 2

A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation

Completed
NCT06570213Early Phase 1

Evaluating The Efficacy Of Combined Cognitive Processing Therapy and Stellate Ganglion Blocks for PTSD

Recruiting
NCT07618611Not Applicable

Identification of Physiological Sleep Indices That Reflect Clinical Improvement and Reduction in Stress Biomarkers After Stellate Ganglion Block in Patients With Posttraumatic Stress Disorder (PTSD)

Not Yet Recruiting
NCT06319534Not Applicable

Stellate Ganglion Block in Bulbar Palsy

Completed
NCT05445921Phase 1

Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction

Completed
NCT06354673Not Applicable

Stellate Ganglion Block Combined With Dexmedetomidine or Subanesthetic Ketamine Infusion for Treatment of Neurostorm.

Completed
NCT07271615Not Applicable

Effect of Preoperative Stellate Ganglion Block on Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting

Recruiting
NCT05169190Not Applicable

Stellate Ganglion Block for PTSD

Active Not Recruiting
NCT05377216Early Phase 1

Characterization of Cardiac Electrophysiological Effects of Autonomic Neuromodulation

Recruiting
NCT06253806Phase 2

Stellate Ganglion Block for COVID-induced Parosmia

Completed
NCT05700279Not Applicable

Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset

Recruiting
NCT06953661Not Applicable

Ultrasound Guided Stellate Ganglion Block in Postural Tachycardia Syndrome

Not Yet Recruiting
NCT07211347Phase 4

Percutaneous Blockade of the Stellate Ganglion in Electrical Storm

Recruiting
NCT07129811Not Applicable

Stellate Ganglion Block in Complex Regional Pain Syndrome

Recruiting
NCT05107752Phase 2

Stellate Ganglion Block to Augment Trauma-focused Therapy Among Veterans With PTSD

Completed
NCT04402840Not Applicable

Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

Completed
NCT06300658Not Applicable

Stellate Ganglion Block for Preserving Arteriovenous Fistula in Hemodialysis Patients Undergoing Major Lower Limb Orthopedic Surgery

Recruiting
NCT04188327Not Applicable

Stellate Ganglion Block in Herpes Zoster

Completed
NCT05652179Not Applicable

SGB Reduces the Incidence and Severity of CSA-AKI

Completed
NCT04445337Phase 1

Stellate Ganglion Blockade in Corona Virus 2019 (COVID-19) Positive Patients

Terminated

Drug Details

Intervention Type
PROCEDURE
Total Trials
68